Syneos Health publishes 2022 health trends

MORRISVILLE, North Carolina, December 21, 2021 (GLOBE NEWSWIRE) – Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today released Health Trends 2022: Insights for Industry Change Agents. From patient-powered design to accelerated integration throughout the product lifecycle, Tendencies report enables organizations to be catalysts for change by anticipating what lies ahead.

The trends for 2022 focus on new models for creating value for stakeholders, the importance of putting people first in every healthcare encounter, and building technological knowledge to accelerate the delivery of therapies that change patients’ lives.

“If there’s one line in this year’s report, it’s this: We are an industry working towards sustainable acceleration,” said Leigh Householder, Managing Director, Omnichannel Strategy, Syneos Health. “The pandemic has forced rapidly evolving innovation, prompting biopharmaceutical organizations around the world to validate real-time information and learning that is now fueling industry change and value creation. “

New models of product development withstand an incredibly demanding and disruptive time, with healthcare professionals tested by high levels of burnout and the biopharmaceutical industry challenged to find and retain key talent. Despite these obstacles, the dynamism and optimism of the market are reborn at the dawn of the new year. Notably, the push to improve diversity, equity and inclusion (DE&I) is changing the way biopharmaceuticals engages communities to improve access and the way the industry builds organizations and teams.

“The human toll of the pace and magnitude of disruption demands a re-examination of every aspect of product development. Simplifying the complex for patients, providers, scientists, clients and every employee is essential, ”said Alistair Macdonald, CEO of Syneos Health. “These trends are driving much-needed changes, including exploring new models to improve stakeholder value, accelerate digital transformation, and advance DE&I to drive innovation. “

The top 10 trends set to catalyze the coming year align around key themes focused on value creation, people and change in the industry.

The creation of value: Ensuring that data and information flows throughout the product lifecycle to deliver on the promise of innovation, creating greater value for all stakeholders.

1. Appropriate acceleration of clinical development
The acceleration will be driven by innovative study design and execution, real-world data engines, flexible decentralized engagement, and dynamic contracts.
2. Engagement optimization loop
The new business models will have two key dimensions: people and digital. Omnichannel engagement will be used to amplify critical human interactions and deliver powerful insights on when and how to act most effectively across all channels.
3. Patient-powered design
As patient voices rise, a long-standing communication gap between patients and those who innovate on their behalf is finally starting to close.

Human centricity: Prioritize the personal relationships at the heart of every healthcare interaction and strengthen them with technology-driven insights.

4. The changing customer interface
Look for significant disruptions in how key stakeholders engage with each other, including a new hybrid domain, evolving roles of Clinical Research Associates (CRAs), new avenues of recruitment, and simplification of the complex.
5. Hire the exhausted healthcare professional
A profession that already faced dangerous levels of burnout has suffered even more in the past two years as it battles a pandemic, lack of access to patients, a shortage of essential resources and isolation from its peers. Engaging them is different now.
6. High expectations for / from top talent
Within a year, we have gone from unprecedented hiring levels in the biopharmaceutical industry in response to the urgent need to support public safety, to many organizations being short-staffed in the face of changing demands. business priorities.
seven. Personal, tailor-made and now possible
According to a According to a recent Syneos Health benchmarking study, biopharmaceutical executives on average rate their use of modern customer engagement and omnichannel infrastructure at six out of 10, significantly better than before the pandemic. In 2022, the transformation is accelerating.

Industry change: Act to tackle public health problems in social policy head-on, leading by example in a newly dynamic environment for innovation.

8. Urgency of representation
Advancing ED&I within biopharmaceutical organizations and among stakeholder populations will be a key strategic priority for the industry in 2022 and beyond.
9. Rx Rep (utation)
The reputation of the pharmaceutical industry experienced an unprecedented resurgence in 2021 – largely due to its rapid response to the pandemic. At the same time, trust in government institutions suffered, leaving manufacturers to fill the void by communicating with scientific rigor and transparency. Maintaining and developing the reputation of the industry will be a key opportunity for 2022.
ten. A new era of market dynamism
After years of response and reaction, the biopharmacy is poised to take bold new steps, leveraging new levels of funding, new resource and partner models to enhance asset value, new centers of excellence global – and even new constraints – to advance innovation in the life sciences.

Implications of Health Trends 2022 – Connect with us to find out more

  • Visit to download the full report.
  • Subscribe to our podcast for more in-depth coverage of the Health trends 2022 and the implications for biopharmaceutical companies in the new year.
  • Follow Syneos Santé on LinkedIn where our leaders will share their views on these trends.

About Syneos Santé
Syneos Health® (Nasdaq: SYNH) is the only fully integrated biopharmaceutical solutions organization. The company, which includes a Contract Research Organization (CRO) and a Contract Sales Organization (CCO), is uniquely designed to accelerate client performance to meet modern market realities. We bring together approximately 28,000 clinical and business minds with the ability to support clients in over 110 countries. Together, we share ideas, use the latest technology and apply advanced business practices to accelerate our customers’ delivery of important therapies to patients.

Find out more about how we are shortening the distance between the lab and life®, visit or subscribe to our podcast.

Investor Relations Contact: Press / media contact:
Ronnie speight Gary Gatyas
Senior Vice President, Investor Relations Executive Director, External Communications
+1 919 745 2745 +1 908 763 3428
[email protected] [email protected]

Maria J. Book